{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,10]],"date-time":"2026-04-10T10:11:34Z","timestamp":1775815894263,"version":"3.50.1"},"reference-count":41,"publisher":"Becaris Publishing Limited","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J. Comp. Eff. Res."],"published-print":{"date-parts":[[2015,8]]},"abstract":"<jats:p>Stroke exacts a huge toll physically, mentally and economically. Antiplatelet therapy is the cornerstone of secondary stroke prevention, and proven drugs available to successfully realize this therapeutic strategy for the long term include aspirin, dipyridamole plus aspirin and clopidogrel. However, government agencies, corporations, health plans and patients desire more information about the clinical- and cost\u2013effectiveness of these established therapies in real-world settings. This paper provides an update on evidence-based secondary stroke prevention with antiplatelet medications, discusses cost-related issues and offers perspective about the future.<\/jats:p>","DOI":"10.2217\/cer.15.22","type":"journal-article","created":{"date-parts":[[2015,8,14]],"date-time":"2015-08-14T16:17:39Z","timestamp":1439569059000},"page":"377-384","source":"Crossref","is-referenced-by-count":10,"title":["Antiplatelet therapies for secondary stroke prevention: an update on clinical and cost\u2013effectiveness"],"prefix":"10.57264","volume":"4","author":[{"given":"Julia M","family":"Rothlisberger","sequence":"first","affiliation":[{"name":"Department of Neurology, Medical University of South Carolina, 96 Jonathan Lucas Street, CSB 301, MSC 606, Charleston, SC 29425, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bruce","family":"Ovbiagele","sequence":"additional","affiliation":[{"name":"Department of Neurology, Medical University of South Carolina, 96 Jonathan Lucas Street, CSB 301, MSC 606, Charleston, SC 29425, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"36897","reference":[{"issue":"3","key":"e_1_3_2_3_2","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1161\/01.cir.0000442015.53336.12","article-title":"Executive summary: heart disease and stroke statistics \u2013 2014 update: a report from the American Heart Association","volume":"129","author":"Go AS","year":"2014","unstructured":"Go AS , Mozaffarian D , Roger VL Executive summary: heart disease and stroke statistics \u2013 2014 update: a report from the American Heart Association . Circulation 129 ( 3 ), 399 \u2013 410 ( 2014 ).","journal-title":"Circulation"},{"issue":"4","key":"e_1_3_2_4_2","first-page":"e29","article-title":"Heart disease and stroke statistics \u2013 2015 update: a report from the American Heart Association","volume":"131","author":"Mozaffarian D","year":"2015","unstructured":"Mozaffarian D , Benjamin EJ , Go AS Heart disease and stroke statistics \u2013 2015 update: a report from the American Heart Association . Circulation 131 ( 4 ), e29 \u2013 e322 ( 2015 ).","journal-title":"Circulation"},{"issue":"7","key":"e_1_3_2_5_2","doi-asserted-by":"crossref","first-page":"2160","DOI":"10.1161\/STR.0000000000000024","article-title":"Guidelines for the prevention of stroke in patients with stroke and transient ischemic attack: a guideline for healthcare professionals from the American Heart Association\/American Stroke Association","volume":"45","author":"Kernan WN","year":"2014","unstructured":"Kernan WN , Ovbiagele B , Black HR Guidelines for the prevention of stroke in patients with stroke and transient ischemic attack: a guideline for healthcare professionals from the American Heart Association\/American Stroke Association . Stroke 45 ( 7 ), 2160 \u2013 2236 ( 2014 ).","journal-title":"Stroke"},{"issue":"1","key":"e_1_3_2_6_2","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1161\/01.STR.24.1.35","article-title":"Classification of subtype of acute ischemic stroke. Definitions for use in a multicenter clinical trial. TOAST. Trial of Org 10172 in acute stroke treatment","volume":"24","author":"Adams HP","year":"1993","unstructured":"Adams HP , Jr , Bendixen BH , Kappelle LJ Classification of subtype of acute ischemic stroke. Definitions for use in a multicenter clinical trial. TOAST. Trial of Org 10172 in acute stroke treatment . Stroke 24 ( 1 ), 35 \u2013 41 ( 1993 ).","journal-title":"Stroke"},{"issue":"7329","key":"e_1_3_2_7_2","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1136\/bmj.324.7329.71","article-title":"Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients","volume":"324","author":"Antithrombotic Trialists C","year":"2002","unstructured":"Antithrombotic Trialists C . Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients . BMJ 324 ( 7329 ), 71 \u2013 86 ( 2002 ).","journal-title":"BMJ"},{"issue":"18","key":"e_1_3_2_8_2","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1056\/NEJM199110313251801","article-title":"A comparison of two doses of aspirin (30 mg vs 283 mg a day) in patients after a transient ischemic attack or minor ischemic stroke","volume":"325","author":"The Dutch TIA Trial Study Group","year":"1991","unstructured":"The Dutch TIA Trial Study Group . A comparison of two doses of aspirin (30 mg vs 283 mg a day) in patients after a transient ischemic attack or minor ischemic stroke . N. Engl. J. Med. 325 ( 18 ), 1261 \u2013 1266 ( 1991 ).","journal-title":"N. Engl. J. Med."},{"issue":"12","key":"e_1_3_2_9_2","doi-asserted-by":"crossref","first-page":"1044","DOI":"10.1136\/jnnp.54.12.1044","article-title":"The United Kingdom Transient Ischaemic Attack (UK-TIA) Aspirin Trial: final results","volume":"54","author":"Farrell B","year":"1991","unstructured":"Farrell B , Godwin J , Richards S , Warlow C . The United Kingdom Transient Ischaemic Attack (UK-TIA) Aspirin Trial: final results . J. Neurol. Neurosurg. Pyschiatry 54 ( 12 ), 1044 \u2013 1054 ( 1991 ).","journal-title":"J. Neurol. Neurosurg. Pyschiatry"},{"issue":"11","key":"e_1_3_2_10_2","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.1001\/archinte.159.11.1248","article-title":"A metaregression analysis of the dose-response effect of aspirin on stroke","volume":"159","author":"Johnson ES","year":"1999","unstructured":"Johnson ES , Lanes SF , Wentworth CE , 3rd , Satterfield MH , Abebe BL , Dicker LW . A metaregression analysis of the dose-response effect of aspirin on stroke . Arch. Intern. Med. 159 ( 11 ), 1248 \u2013 1253 ( 1999 ).","journal-title":"Arch. Intern. Med."},{"issue":"3","key":"e_1_3_2_11_2","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1161\/STR.0b013e318284056a","article-title":"Guidelines for the early management of patients with acute ischemic stroke: a guideline for healthcare professionals from the American Heart Association\/American Stroke Association","volume":"44","author":"Jauch EC","year":"2013","unstructured":"Jauch EC , Saver JL , Adams HP Jr Guidelines for the early management of patients with acute ischemic stroke: a guideline for healthcare professionals from the American Heart Association\/American Stroke Association . Stroke 44 ( 3 ), 870 \u2013 947 ( 2013 ).","journal-title":"Stroke"},{"issue":"2","key":"e_1_3_2_12_2","first-page":"1","article-title":"The Caprie Trial: culmination of the preregistration program for clopidogrel. Clopidogrel versus aspirin in patients at risk of ischaemic events","volume":"25","author":"Gent M","year":"1999","unstructured":"Gent M . The Caprie Trial: culmination of the preregistration program for clopidogrel. Clopidogrel versus aspirin in patients at risk of ischaemic events . Semin. Thromb. Hemost. 25 ( Suppl. 2 ), 1 \u2013 2 ( 1999 ).","journal-title":"Semin. Thromb. Hemost."},{"issue":"7","key":"e_1_3_2_13_2","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1056\/NEJMoa010746","article-title":"Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without st-segment elevation","volume":"345","author":"Yusuf S","year":"2001","unstructured":"Yusuf S , Zhao F , Mehta SR Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without st-segment elevation . N. Engl. J. Med. 345 ( 7 ), 494 \u2013 502 ( 2001 ).","journal-title":"N. Engl. J. Med."},{"issue":"9431","key":"e_1_3_2_14_2","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1016\/S0140-6736(04)16721-4","article-title":"Aspirin and clopidogrel compared with clopidogrel alone after recent ischaemic stroke or transient ischaemic attack in high-risk patients (match): randomised, double-blind, placebo-controlled trial","volume":"364","author":"Diener HC","year":"2004","unstructured":"Diener HC , Bogousslavsky J , Brass LM Aspirin and clopidogrel compared with clopidogrel alone after recent ischaemic stroke or transient ischaemic attack in high-risk patients (match): randomised, double-blind, placebo-controlled trial . Lancet 364 ( 9431 ), 331 \u2013 337 ( 2004 ).","journal-title":"Lancet"},{"issue":"20","key":"e_1_3_2_15_2","doi-asserted-by":"crossref","first-page":"2066","DOI":"10.1056\/NEJMoa0901301","article-title":"Effect of clopidogrel added to aspirin in patients with atrial fibrillation","volume":"360","author":"Investigators A","year":"2009","unstructured":"Investigators A , Connolly SJ , Pogue J Effect of clopidogrel added to aspirin in patients with atrial fibrillation . N. Engl. J. Med. 360 ( 20 ), 2066 \u2013 2078 ( 2009 ).","journal-title":"N. Engl. J. Med."},{"issue":"9","key":"e_1_3_2_16_2","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1056\/NEJMoa1204133","article-title":"Effects of clopidogrel added to aspirin in patients with recent lacunar stroke","volume":"367","author":"Investigators SPS","year":"2012","unstructured":"Investigators SPS , Benavente OR , Hart RG Effects of clopidogrel added to aspirin in patients with recent lacunar stroke . N. Engl. J. Med. 367 ( 9 ), 817 \u2013 825 ( 2012 ).","journal-title":"N. Engl. J. Med."},{"key":"e_1_3_2_17_2","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.1161\/STROKEAHA.114.008422","article-title":"Efficacy of antiplatelet therapy in secondary prevention following lacunar stroke","volume":"46","author":"Kowk CS","year":"2015","unstructured":"Kowk CS , Shoamanesh A , Copley HC , Myint PK , Loke YK , Benavente OR . Efficacy of antiplatelet therapy in secondary prevention following lacunar stroke . Stroke 46 , 1014 \u2013 1023 ( 2015 ).","journal-title":"Stroke"},{"issue":"4","key":"e_1_3_2_18_2","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1161\/CIRCULATIONAHA.109.885194","article-title":"Cytochrome 2c19*17 allelic variant, platelet aggregation, bleeding events, and stent thrombosis in clopidogrel-treated patients with coronary stent placement","volume":"121","author":"Sibbing D","year":"2010","unstructured":"Sibbing D , Koch W , Gebhard D Cytochrome 2c19*17 allelic variant, platelet aggregation, bleeding events, and stent thrombosis in clopidogrel-treated patients with coronary stent placement . Circulation 121 ( 4 ), 512 \u2013 518 ( 2010 ).","journal-title":"Circulation"},{"key":"e_1_3_2_19_2","first-page":"321","article-title":"Efficacy versus safety: the dilemma of using novel platelet inhibitors for the treatment of patients with ischemic stroke and coronary artery disease","volume":"10","author":"Iannopollo G","year":"2014","unstructured":"Iannopollo G , Camporotondo R , De Ferrari GM , Leonardi S . Efficacy versus safety: the dilemma of using novel platelet inhibitors for the treatment of patients with ischemic stroke and coronary artery disease . Ther. Clin. Risk Manag. 10 , 321 \u2013 329 ( 2014 ).","journal-title":"Ther. Clin. Risk Manag."},{"issue":"9665","key":"e_1_3_2_20_2","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1016\/S0140-6736(09)60441-4","article-title":"Prasugrel compared with clopidogrel in patients undergoing percutaneous coronary intervention for st-elevation myocardial infarction (triton-timi 38): double-blind, randomised controlled trial","volume":"373","author":"Montalescot G","year":"2009","unstructured":"Montalescot G , Wiviott SD , Braunwald E Prasugrel compared with clopidogrel in patients undergoing percutaneous coronary intervention for st-elevation myocardial infarction (triton-timi 38): double-blind, randomised controlled trial . Lancet 373 ( 9665 ), 723 \u2013 731 ( 2009 ).","journal-title":"Lancet"},{"issue":"20","key":"e_1_3_2_21_2","doi-asserted-by":"crossref","first-page":"2001","DOI":"10.1056\/NEJMoa0706482","article-title":"Prasugrel versus clopidogrel in patients with acute coronary syndromes","volume":"357","author":"Wiviott SD","year":"2007","unstructured":"Wiviott SD , Braunwald E , Mccabe CH Prasugrel versus clopidogrel in patients with acute coronary syndromes . N. Engl. J. Med. 357 ( 20 ), 2001 \u2013 2015 ( 2007 ).","journal-title":"N. Engl. J. Med."},{"issue":"10","key":"e_1_3_2_22_2","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1016\/S1474-4422(10)70198-8","article-title":"Cilostazol for prevention of secondary stroke (csps 2): an aspirin-controlled, double-blind, randomised non-inferiority trial","volume":"9","author":"Shinohara Y","year":"2010","unstructured":"Shinohara Y , Katayama Y , Uchiyama S Cilostazol for prevention of secondary stroke (csps 2): an aspirin-controlled, double-blind, randomised non-inferiority trial . Lancet Neurol. 9 ( 10 ), 959 \u2013 968 ( 2010 ).","journal-title":"Lancet Neurol."},{"issue":"6","key":"e_1_3_2_23_2","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1016\/S1474-4422(08)70094-2","article-title":"Cilostazol as an alternative to aspirin after ischaemic stroke: a randomised, double-blind, pilot study","volume":"7","author":"Huang Y","year":"2008","unstructured":"Huang Y , Cheng Y , Wu J Cilostazol as an alternative to aspirin after ischaemic stroke: a randomised, double-blind, pilot study . Lancet Neurol. 7 ( 6 ), 494 \u2013 499 ( 2008 ).","journal-title":"Lancet Neurol."},{"issue":"1","key":"e_1_3_2_24_2","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0022-510X(96)00308-5","article-title":"European stroke prevention study. 2. Dipyridamole and acetylsalicylic acid in the secondary prevention of stroke","volume":"143","author":"Diener HC","year":"1996","unstructured":"Diener HC , Cunha L , Forbes C , Sivenius J , Smets P , Lowenthal A . European stroke prevention study. 2. Dipyridamole and acetylsalicylic acid in the secondary prevention of stroke . J. Neurol. Sci. 143 ( 1\u20132 ), 1 \u2013 13 ( 1996 ).","journal-title":"J. Neurol. Sci."},{"issue":"9523","key":"e_1_3_2_25_2","doi-asserted-by":"crossref","first-page":"1665","DOI":"10.1016\/S0140-6736(06)68734-5","article-title":"Aspirin plus dipyridamole versus aspirin alone after cerebral ischaemia of arterial origin (esprit): randomised controlled trial","volume":"367","author":"Group ES","year":"2006","unstructured":"Group ES , Halkes PH , Van Gijn J , Kappelle LJ , Koudstaal PJ , Algra A . Aspirin plus dipyridamole versus aspirin alone after cerebral ischaemia of arterial origin (esprit): randomised controlled trial . Lancet 367 ( 9523 ), 1665 \u2013 1673 ( 2006 ).","journal-title":"Lancet"},{"issue":"12","key":"e_1_3_2_26_2","doi-asserted-by":"crossref","first-page":"1238","DOI":"10.1056\/NEJMoa0805002","article-title":"Aspirin and extended-release dipyridamole versus clopidogrel for recurrent stroke","volume":"359","author":"Sacco RL","year":"2008","unstructured":"Sacco RL , Diener HC , Yusuf S Aspirin and extended-release dipyridamole versus clopidogrel for recurrent stroke . N. Engl. J. Med. 359 ( 12 ), 1238 \u2013 1251 ( 2008 ).","journal-title":"N. Engl. J. Med."},{"issue":"3","key":"e_1_3_2_27_2","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1161\/STROKEAHA.111.000433","article-title":"Efficacy and safety of vorapaxar in patients with prior ischemic stroke","volume":"44","author":"Morrow DA","year":"2013","unstructured":"Morrow DA , Alberts MJ , Mohr JP Efficacy and safety of vorapaxar in patients with prior ischemic stroke . Stroke 44 ( 3 ), 691 \u2013 698 ( 2013 ).","journal-title":"Stroke"},{"issue":"15","key":"e_1_3_2_28_2","doi-asserted-by":"crossref","first-page":"1656","DOI":"10.1161\/CIRCULATIONAHA.113.003187","article-title":"Early dual versus mono antiplatelet therapy for acute non-cardioembolic ischemic stroke or transient ischemic attack: an updated systematic review and meta-analysis","volume":"128","author":"Wong KS","year":"2013","unstructured":"Wong KS , Wang Y , Leng X Early dual versus mono antiplatelet therapy for acute non-cardioembolic ischemic stroke or transient ischemic attack: an updated systematic review and meta-analysis . Circulation 128 ( 15 ), 1656 \u2013 1666 ( 2013 ).","journal-title":"Circulation"},{"issue":"31","key":"e_1_3_2_29_2","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3310\/hta15310","article-title":"Clopidogrel and modified-release dipyridamole for the prevention of occlusive vascular events (review of technology appraisal no. 90): a systematic review and economic analysis","volume":"15","author":"Greenhalgh J","year":"2011","unstructured":"Greenhalgh J , Bagust A , Boland A Clopidogrel and modified-release dipyridamole for the prevention of occlusive vascular events (review of technology appraisal no. 90): a systematic review and economic analysis . Health Technology Assessment 15 ( 31 ), 1 \u2013 178 ( 2011 ).","journal-title":"Health Technology Assessment"},{"issue":"7","key":"e_1_3_2_30_2","doi-asserted-by":"crossref","first-page":"463","DOI":"10.7326\/0003-4819-159-7-201310010-00006","article-title":"Risk-benefit profile of long-term dual- versus single-antiplatelet therapy among patients with ischemic stroke: a systematic review and meta-analysis","volume":"159","author":"Lee M","year":"2013","unstructured":"Lee M , Saver JL , Hong KS , Rao NM , Wu YL , Ovbiagele B . Risk-benefit profile of long-term dual- versus single-antiplatelet therapy among patients with ischemic stroke: a systematic review and meta-analysis . Ann. Intern. Med. 159 ( 7 ), 463 \u2013 470 ( 2013 ).","journal-title":"Ann. Intern. Med."},{"issue":"8","key":"e_1_3_2_31_2","doi-asserted-by":"crossref","first-page":"2361","DOI":"10.1161\/STR.0b013e31829734f2","article-title":"Forecasting the future of stroke in the united states: a policy statement from the American Heart Association and American Stroke Association","volume":"44","author":"Ovbiagele B","year":"2013","unstructured":"Ovbiagele B , Goldstein LB , Higashida RT Forecasting the future of stroke in the united states: a policy statement from the American Heart Association and American Stroke Association . Stroke 44 ( 8 ), 2361 \u2013 2375 ( 2013 ).","journal-title":"Stroke"},{"key":"e_1_3_2_32_2","unstructured":"Using antiplatelet drugs to treat: heart disease heart attacks and strokes. Comparing effectivelness safety and price. Consumer reports\n                    . \n                    http:\/\/consumerhealthchoices.org\/wp-content\/uploads\/2012\/08\/BBD-Antiplatelets-Full.pdf\n                    ."},{"key":"e_1_3_2_33_2","unstructured":"Consumer Reports Antiplatelet drugs: do you need one to help prevent a heart attack or stroke?"},{"issue":"5","key":"e_1_3_2_34_2","doi-asserted-by":"crossref","first-page":"577","DOI":"10.2165\/00019053-199916050-00013","article-title":"Cost\u2013effectiveness analysis of antiplatelet therapy in the prevention of recurrent stroke in the UK. Aspirin, dipyridamole and aspirin-dipyridamole","volume":"16","author":"Chambers M","year":"1999","unstructured":"Chambers M , Hutton J , Gladman J . Cost\u2013effectiveness analysis of antiplatelet therapy in the prevention of recurrent stroke in the UK. Aspirin, dipyridamole and aspirin-dipyridamole . Pharmacoeconomics 16 ( 5 Pt 2 ), 577 \u2013 593 ( 1999 ).","journal-title":"Pharmacoeconomics"},{"issue":"3","key":"e_1_3_2_35_2","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1016\/S0149-2918(00)80041-7","article-title":"Aspirin plus extended-release dipyridamole or clopidogrel compared with aspirin monotherapy for the prevention of recurrent ischemic stroke: a cost\u2013effectiveness analysis","volume":"22","author":"Shah H","year":"2000","unstructured":"Shah H , Gondek K . Aspirin plus extended-release dipyridamole or clopidogrel compared with aspirin monotherapy for the prevention of recurrent ischemic stroke: a cost\u2013effectiveness analysis . Clin. Ther. 22 ( 3 ), 362 \u2013 370 ; discussion 360\u2013361 ( 2000 ).","journal-title":"Clin. Ther."},{"issue":"2","key":"e_1_3_2_36_2","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1111\/j.1440-1746.2011.07029.x","article-title":"Anti-platelet therapy and managing ulcer risk","volume":"27","author":"Chan FK","year":"2012","unstructured":"Chan FK . Anti-platelet therapy and managing ulcer risk . J. Gastroenterol. Hepatol. 27 ( 2 ), 195 \u2013 199 ( 2012 ).","journal-title":"J. Gastroenterol. Hepatol."},{"issue":"9","key":"e_1_3_2_37_2","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1080\/21548331.1993.11442919","article-title":"Ticlopidine and stroke prevention","volume":"28","author":"Harbison JW","year":"1993","unstructured":"Harbison JW . Ticlopidine and stroke prevention . Hosp. Pract. 28 ( 9A ), 20 \u2013 22 ( 1993 ).","journal-title":"Hosp. Pract."},{"issue":"3","key":"e_1_3_2_38_2","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1111\/j.1747-4949.2011.00602.x","article-title":"Singapore Ministry of Health Clinical Practice Guidelines Workgroup on S, Transient Ischaemic. A Singapore Ministry of Health Clinical Practice Guidelines on stroke and transient ischemic attacks","volume":"6","author":"Venketasubramanian N","year":"2011","unstructured":"Venketasubramanian N , Pwee KH , Chen CP . Singapore Ministry of Health Clinical Practice Guidelines Workgroup on S, Transient Ischaemic. A Singapore Ministry of Health Clinical Practice Guidelines on stroke and transient ischemic attacks . Int. J. Stroke 6 ( 3 ), 251 \u2013 258 ( 2011 ).","journal-title":"Int. J. Stroke"},{"issue":"22","key":"e_1_3_2_39_2","doi-asserted-by":"crossref","first-page":"2088","DOI":"10.1056\/NEJMsa1107913","article-title":"Full coverage for preventive medications after myocardial infarction","volume":"365","author":"Choudhry NK","year":"2011","unstructured":"Choudhry NK , Avorn J , Glynn RJ Full coverage for preventive medications after myocardial infarction . N. Engl. J. Med. 365 ( 22 ), 2088 \u2013 2097 ( 2011 ).","journal-title":"N. Engl. J. Med."},{"issue":"6","key":"e_1_3_2_40_2","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1111\/ijs.12129","article-title":"Platelet-oriented inhibition in new TIA and minor ischemic stroke (POINT) trial: rationale and design","volume":"8","author":"Johnston SC","year":"2013","unstructured":"Johnston SC , Easton JD , Farrant M Platelet-oriented inhibition in new TIA and minor ischemic stroke (POINT) trial: rationale and design . Int. J. Stroke 8 ( 6 ), 479 \u2013 483 ( 2013 ).","journal-title":"Int. J. Stroke"},{"issue":"3","key":"e_1_3_2_41_2","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1111\/ijs.12445","article-title":"Statistical analysis plan for the \u2018Triple Antiplatelets for Reducing Dependency after Ischaemic Stroke\u2019 (TARDIS) trial","volume":"10","author":"Bath PM","year":"2015","unstructured":"Bath PM , Robson K , Woodhouse LJ Statistical analysis plan for the \u2018Triple Antiplatelets for Reducing Dependency after Ischaemic Stroke\u2019 (TARDIS) trial . Int. J. Stroke 10 ( 3 ), 449 \u2013 451 ( 2015 ).","journal-title":"Int. J. Stroke"},{"key":"e_1_3_2_42_2","unstructured":"AstraZeneca\n                    . \n                    SOCRATES \u2013 Acute Stroke Or Transient IsChaemic Attack TReated With Aspirin or Ticagrelor and Patient OutcomES\n                    . \n                    ClinicalTrials.gov\n                    . \n                    Bethesda MD\n                    : \n                    National Library of Medicine (US)\n                     (\n                    2000\n                    ). \n                    www.clinicaltrials.gov\/ct2\/show\/NCT01994720\n                    ."},{"issue":"9749","key":"e_1_3_2_43_2","doi-asserted-by":"crossref","first-page":"1320","DOI":"10.1016\/S0140-6736(10)61274-3","article-title":"Effect of CYP2C19 and ABCB1 single nucleotide polymorphisms on outcomes of treatment with ticagrelor versus clopidogrel for acute coronary syndromes: a genetic substudy of the PLATO trial","volume":"376","author":"Wallentin L","year":"2010","unstructured":"Wallentin L , James S , Storey RF Effect of CYP2C19 and ABCB1 single nucleotide polymorphisms on outcomes of treatment with ticagrelor versus clopidogrel for acute coronary syndromes: a genetic substudy of the PLATO trial . Lancet 376 ( 9749 ), 1320 \u2013 1328 ( 2010 ).","journal-title":"Lancet"}],"container-title":["Journal of Comparative Effectiveness Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/becarispublishing.com\/doi\/pdf\/10.2217\/cer.15.22","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,3,19]],"date-time":"2023-03-19T12:50:11Z","timestamp":1679230211000},"score":1,"resource":{"primary":{"URL":"https:\/\/becarispublishing.com\/doi\/10.2217\/cer.15.22"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,8]]},"references-count":41,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2015,8]]}},"alternative-id":["10.2217\/cer.15.22"],"URL":"https:\/\/doi.org\/10.2217\/cer.15.22","relation":{},"ISSN":["2042-6305","2042-6313"],"issn-type":[{"value":"2042-6305","type":"print"},{"value":"2042-6313","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,8]]}}}